Hattie Hayes

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Stefano Mercuri, MD, speaks about his team's August Deutman award-winning research on retinitis pigmentosa and Rho gene mutations

Alexandra Miere, MD, PhD, says oculomics is the next big thing in eye care.

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.

Clare Bailey, MD, shared data from the multi-country study on faricimab for patients with DME and nAMD

How retinal imaging can provide clinicians a deeper understanding of myopia

New research and EURETINA highlights from the director of the "underdog" eye clinic

Nicole Eter, MD, discussed the use of a magnification implant being used in patients with geographic atrophy (GA) at from this year's EURETINA congress being held in Barcelona, Spain, which took place September 19-22, 2024.

Pearls from PULSAR, PHOTON, and working practitioners

Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

Why having a set process for diagnostic imaging is crucial to patient outcomes

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

Fasika Woreta, MD, discussed the Roman-Barnes lecture and the cornea care landscape ahead of the National Medical Association meeting.

John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.

Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Adverum CEO Laurent Fischer spoke exclusively to Modern Retina about the 26-week interim analysis.

Jennifer I. Lim, MD, FARVO, FASRS, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss her ASRS 2024 presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy."

The organization has secured £72.75 million for its new eye health center.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.